A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)

This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.

Inclusion Criteria:

• Women who are 60 to 90 years of age may be eligible to participate
• Bone mineral density (BMD) T-Score at hip or spine must be less than -2.5

Exclusion Criteria:

• BMD T-Score at the hip or the spine of less than -4.0
• Patients with any severe or more than two moderate vertebral fractures on spinal x-ray at entry